Table 1.

Zika vaccine candidate platforms and components

Platform technology	Type
Live attenuated	Infectious clone based with mutations Codon pair de-optimized Plasmid-launched live attenuated vaccine Chimeric prM + E based on either dengue, Japanese encephalitis or yellow fever backbones Single round replicating viruses
Inactivated	Formalin-inactivated purified whole virus particle
Recombinant protein	N-terminal 80% envelope protein N-terminal 90% envelope protein Envelope protein domain III NS1
Virus-like particles (VLPs)	prM + E protein
Live vectored	Measles virus Vaccinia
None-live vectored	Replication deficient chimpanzee adenovirus Replication deficient human adenovirus Replication defective rhesus adenovirus Replication defective poxvirus
DNA	prM + E prM + E + NS1
RNA	prM + E

*prM = pre-membrane; E = envelope; NS1 = nonstructural protein 1